drugset / Trial / NCT02686645

Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection

NCT02686645

Phase 2/3 Unknown 50 enrolled Queen Elizabeth II Health Sciences Centre
NaSingle-groupOpen-labelTreatment

Summary

Interventional, single arm, single-centre trial to evaluate the effectiveness and safety of fecal microbiota therapy (FMT) in the investigators population.

Timeline

Start
2016-12
Primary completion
2021-12
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Fecal Microbiota Other / unclassified Rectal
Background Loperamide Small molecule 4 mg Oral
Background Metronidazole Small molecule 500 mg Oral
Background Vancomycin Other / unclassified 125 mg Oral